View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 11, 2016updated 18 Jul 2018 9:03am

5 of the best: CTA’s Clinical News Roundup (4th–9th July)

CTA spotlights five of the best industry related stories from the past week

By Staff Writer

Juno Therapeutics clinical trial put on hold after 2 patients died – CNBC News

CNBC News reports the FDA intervened and placed a phase 2 clinical on hold last week after two patients died. The drug, being developed by Juno Therapeutics, was being used to treat patients with leukaemia. 

“The company said that the deaths occurred after it added fludarabine, a chemotherapy drug, to its pre-conditioning regimen. Juno suggested to the FDA that clinical trials continue using cyclophosphamide pre-conditioning on its own.”

For more on this story, click here.


Ampio Pharmaceuticals fails second Phase 3 Osteoarthritis Trial – AO Markets

AO Markets reported last week that shares of Ampio Pharmaceuticals stock fell by 61 percent after the company revealed a phase 3 clinical trial treating patients with osteoarthritis had failed.

The company’s drug, Ampion, was being tested “in a 480 patient trial in patients with osteoarthritis of the knee.” It is believed the drug failed to meet the clinical trial’s primary endpoint.

To learn more on the latest developments of this story, finishing reading here.


Salmonella 'game-changer' could shrink cancer cells – BBC News

According to the BBC, researchers at Swansea University revealed they may have made a breakthrough that could transform treatment for prostate cancer.

By using a strain of salmonella bacteria, scientists at Swansea University’s School of Medicine have found a way to shrink cancer cells, isolating the tumour while leaving healthy tissues unaffected.

Experts say this novel treatment could be a ‘game changer’ in oncology.

For more on this groundbreaking story, click here.


New NIH-Funded Center to Study Inefficiencies in Clinical Trials – Duke Today

Last week Duke Today revealed researchers from Vanderbilt University Medical Center and Duke Clinical Research Institute received a federal grant to learn how multisite clinical trials can be carried more rapidly and efficiently.

The $26.5 million grant has received the backing of the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). It is believed the funds are essential in establishing the joint Trial Innovation Network, which is the newest part of the Clinical and Translational Science Award Program.

Click here to finish reading this story.


Many Clinical Trials Not Listed at Clinical Study Data Request Website – Endochronology Advisor

According to a research letter published in the Journal of the American Medical Association, roughly 50 percent of studies listed on are registered in its data-sharing repository.

Experts from Paris Descartes University in France studied “the proportion of randomized clinical trials (RCTs) registered at that was listed on the Clinical Study Data Request (CSDR) data-sharing repository website.

“The researchers found that there were 966 RCTs (462,751 participants) for the 61 targeted drugs from the 4 sponsors; 53 percent of these trials (with 74 percent of participants) were listed at CSDR.”

To finish this story, continue reading here.


PHOTO CREDIT: Jon S via Flickr Creative Commons

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena